Amedeo Smart

Free Medical Literature Service

 

Amedeo

Hepatitis
  Free Subscription

Articles published in
J Infect Dis
    October 2026
  1. JOHN K, Voss ML, Al Aoua S, Franck M, et al
    Concomitant Liver Steatosis in Chronic Hepatitis B Virus Infection Is Linked to a Distinct Cytokine Profile and Reduced Viral Load.
    J Infect Dis. 2026;234:556-563.
    >> Share

    September 2026
  2. SHIHA G, Ebara M, Hassan A, Toyoda H, et al
    A novel decentralized rapid test for detection of HCV antigens using smart polymer technology: a prospective multinational study.
    J Infect Dis. 2026 Sep 17:jiag450. doi: 10.1093.
    >> Share

    July 2026
  3. ELTAHAN R, Visser BJ, Biswas S, Ishida Y, et al
    Characterization of hepatitis B virus in blood donors who were disqualified based on testing: genotype distribution, infectivity, and replicative fitness in human hepatocytes.
    J Infect Dis. 2026 Jul 31:jiag400. doi: 10.1093.
    >> Share

  4. PAGE K, Goyal A, Cotler SJ, Mathews G, et al
    Reply to Akiyama and Berk: Response-Guided HCV Therapy and the Imperative to Treat in Carceral Settings.
    J Infect Dis. 2026 Jul 18:jiag374. doi: 10.1093.
    >> Share

  5. AKIYAMA MJ, Berk J
    Shortening HCV Treatment in U.S. Jails: Opportunities and Implementation Considerations.
    J Infect Dis. 2026 Jul 18:jiag373. doi: 10.1093.
    >> Share

    June 2026
  6. RAN Y, Zhu M, Wang K, Xia Y, et al
    Immune Checkpoint Inhibitor-Induced Rapid Decline in Hepatitis B Virus Markers Improves the Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients.
    J Infect Dis. 2026;233:1015-1026.
    >> Share

    May 2026
  7. MUELLER BROWN K, Kindsvogel AM, Petnuch SE, Freeman TL, et al
    Live-attenuated Rift Valley fever virus vaccination leads to durable, protective immunity independent of sex in C57BL/6 mice.
    J Infect Dis. 2026 May 15:jiag266. doi: 10.1093.
    >> Share

  8. GOYAL A, Cotler SJ, Matthews GV, Page K, et al
    Modeling predicts shortening of DAA treatment duration to 5 weeks in individuals with recent or chronic infection with HCV RNA negativity at day 7 on treatment.
    J Infect Dis. 2026 May 9:jiag260. doi: 10.1093.
    >> Share

    April 2026
  9. WILBURN L, Bui HL, Akampurira P, Ddamba R, et al
    Schistosoma mansoni Infections Are Associated With Fecal Calprotectin Markers of Gut Inflammation After Accounting for HIV, Hepatitis B, and Malaria.
    J Infect Dis. 2026 Apr 29:jiag094. doi: 10.1093.
    >> Share

  10. SOLIMAN R, Hassan AA, Shiha G
    Rapid HCV diagnostics: aligning molecular innovation with real-world elimination needs.
    J Infect Dis. 2026 Apr 8:jiag207. doi: 10.1093.
    >> Share

  11. REED JL, Butzler MA, Hawkins CA, Manabe YC, et al
    Reply to Soliman et al, Rapid HCV diagnostics: aligning molecular innovation with real-world elimination needs.
    J Infect Dis. 2026 Apr 8:jiag208. doi: 10.1093.
    >> Share

    March 2026
  12. MANI M, Clipman SJ, Bailey JR, Sterling RK, et al
    Single-cell hepatitis B sequencing reveals distinct viral infection events consistent with superinfection.
    J Infect Dis. 2026 Mar 20:jiag181. doi: 10.1093.
    >> Share

  13. AREGAY A, Friese J, Porrez S, Leroux-Roels I, et al
    Induction of a Th1-Type Polyfunctional T Cell Response by the four-segmented Rift Valley Fever candidate vaccine in humans.
    J Infect Dis. 2026 Mar 9:jiag138. doi: 10.1093.
    >> Share

    February 2026
  14. KEGBEVI KB, Febriani Y, Sauvageau C, Ursu MM, et al
    Immunogenicity of two versus three doses of hepatitis B vaccine when administered to children aged 2-18 months: a randomized clinical trial.
    J Infect Dis. 2026 Feb 25:jiag122. doi: 10.1093.
    >> Share

  15. NAIR N, Friese J, Schreur PJW, Osterhaus ADME, et al
    Efficient sensing of a four-segmented Rift Valley fever virus vaccine candidate by human monocytes.
    J Infect Dis. 2026 Feb 13:jiag085. doi: 10.1093.
    >> Share

  16. BOBADILLA R, Kim AY
    Immune Checkpoint Inhibition Therapy Beyond the Tumor: Implications for Hepatitis B Virus in Hepatocellular Carcinoma.
    J Infect Dis. 2026 Feb 4:jiag058. doi: 10.1093.
    >> Share

    January 2026
  17. FANTILLI AC, Pisano MB, Martinez Wassaf M, Di Cola G, et al
    Hepatitis E Virus Infection in Patients With Chronic Liver Diseases: A Latin American Multicenter Study.
    J Infect Dis. 2026 Jan 28:jiaf615. doi: 10.1093.
    >> Share

  18. APPLEGATE TL, Grebely J
    When Time Is of the Essence: Hepatitis C Virus RNA Point-of-Care Testing in 15 Minutes Becomes a Reality.
    J Infect Dis. 2026 Jan 22:jiaf652. doi: 10.1093.
    >> Share

  19. WEN A
    CXCR6 in the Blood Is Not the Liver: Clarifying NK-Cell 'Homing' and Post-Cure ADCC Imprints in Acute Hepatitis C.
    J Infect Dis. 2026 Jan 21:jiag044. doi: 10.1093.
    >> Share

  20. BAKAMUTUMAHO B, Juma J, Clancey E, Nyakarahuka L, et al
    Hyperendemicity of Rift Valley Fever in Southwestern Uganda Associated With the Rapidly Evolving Lineage C Viruses.
    J Infect Dis. 2026;233:e77-e88.
    >> Share

    December 2025
  21. STRUNZ B, Zhan Q, Khera T, Hengst J, et al
    Transient interferon-driven NK cell activation in acute hepatitis C.
    J Infect Dis. 2025 Dec 27:jiaf654. doi: 10.1093.
    >> Share

  22. CHOWDHURY A, Garcia BG, Zahoor MA, Fadl ElMawla N, et al
    A rapid assay for HCV RNA detection using RT-LAMP coupled CRISPR-Cas12b based strategy.
    J Infect Dis. 2025 Dec 16:jiaf609. doi: 10.1093.
    >> Share

  23. REED JL, Butzler MA, Hawkins CA, Manabe YC, et al
    Development of a Rapid Automated Point-of-Care Test for Hepatitis C Viral RNA on the DASH(R) Rapid PCR System.
    J Infect Dis. 2025 Dec 10:jiaf608. doi: 10.1093.
    >> Share

  24. GHORBANI M, Kvedaraite A, Al-Manei K, Too CB, et al
    Oral Microbiome Diversity Matters on Nucleos(t)ide Analogue Cessation in Chronic Hepatitis B.
    J Infect Dis. 2025 Dec 2:jiaf591. doi: 10.1093.
    >> Share

    November 2025
  25. HUME SJ, Visvanathan K, Cheng K, Jackson K, et al
    Anti-HBs immune complex levels: A novel marker of hepatitis flare following nucleos(t)ide analogue withdrawal in HBeAg-negative chronic hepatitis B.
    J Infect Dis. 2025 Nov 14:jiaf569. doi: 10.1093.
    >> Share

    October 2025
  26. SKOVGAARD ET, Wiggers T, Karsdal M, Goetze JP, et al
    Serum markers of fibroinflammatory activity PRO-C3 and CPa9-HNE are associated with liver-related outcomes in patients with Chronic Hepatitis C.
    J Infect Dis. 2025 Oct 31:jiaf552. doi: 10.1093.
    >> Share

  27. LI X, Shi M, Wang X, Guo F, et al
    Non-invasive detection of occult yet significant liver pathology in ALT-normal chronic hepatitis B: a multicenter study.
    J Infect Dis. 2025 Oct 30:jiaf554. doi: 10.1093.
    >> Share

  28. CHEN J, Huang Z, Yang X, Yang Y, et al
    Predictors of Durable Hepatitis B Surface Antigen Loss After Pegylated Interferon-Based Therapy in Patients with Hepatitis B e Antigen-Negative Chronic Hepatitis B: A Multicenter Real-World Study.
    J Infect Dis. 2025;232:953-960.
    >> Share

  29. DAWES BE, De La Mota-Peynado A, Rezende IM, Buyukcangaz EK, et al
    Rift Valley Fever Virus Infectivity in Milk Stored at a Wide Range of Temperatures.
    J Infect Dis. 2025;232:e661-e670.
    >> Share

    August 2025
  30. KOYUNCU A, Nesbitt R, Alvarez C, Asilaza KV, et al
    Diagnostic performance and kinetics of hepatitis E viral RNA and IgM antibody test positivity in a genotype 1 outbreak in South Sudan.
    J Infect Dis. 2025 Aug 14:jiaf436. doi: 10.1093.
    >> Share

  31. YU H, Li B, Guo H, Li L, et al
    SLC22A1 Resists Hepatitis B Virus by Activating the JAK/STAT Pathway and Predicts the Effect of Pegylated Interferon alpha-Based Therapy on Chronic Hepatitis B.
    J Infect Dis. 2025;232:474-484.
    >> Share

  32. MADUT DB, Rubach MP, Allan KJ, Thomas KM, et al
    Epidemiologic and Genomic Characterization of an Outbreak of Rift Valley Fever Among Humans and Dairy Cattle in Northern Tanzania.
    J Infect Dis. 2025;232:298-307.
    >> Share

  33. GAO Q, Lan X, Yang F, Yu H, et al
    Prognostic Divergence in HIV/HBV vs. HBV- Associated HCC after Resection: Intrahepatic Pre-S Deletions Mutants and T-cell Depletion under Viral Suppression.
    J Infect Dis. 2025 Aug 14:jiaf433. doi: 10.1093.
    >> Share

    July 2025
  34. VO-QUANG E, Rodriguez C, Ly A, Ndow G, et al
    Virological tools fail to properly identify "unusual" hepatitis C virus subtypes resistant to direct-acting antiviral drugs in The Gambia.
    J Infect Dis. 2025 Jul 22:jiaf378. doi: 10.1093.
    >> Share

    June 2025
  35. BARAGATTI M, Abdoullah B, Gomez N, Ayhan N, et al
    Seroepidemiological Reconstruction of Long-term Rift Valley Fever Virus Circulation in Nouakchott, Mauritania.
    J Infect Dis. 2025;231:e853-e861.
    >> Share

    May 2025
  36. WEGERMANN K, Lucas JE, Dubois L, Mangus R, et al
    Plasma lipid metabolites differentiate metabolic from viral chronic liver disease.
    J Infect Dis. 2025 May 23:jiaf270. doi: 10.1093.
    >> Share

  37. GRANTZ KH, Anantharam R, Kandathil AJ, Quinn J, et al
    Multiple approaches to genetic sequencing to identify hepatitis C virus reinfection among people who inject drugs.
    J Infect Dis. 2025 May 15:jiaf235. doi: 10.1093.
    >> Share

    April 2025
  38. NDOW G, Bangura R, Vo-Quang E, Touray F, et al
    Residual risk of hepatitis B virus (HBV) mother-to-child transmission and gaps in HBV care cascades among pregnant women in The Gambia: the INFANT-B study.
    J Infect Dis. 2025 Apr 30:jiaf214. doi: 10.1093.
    >> Share

  39. BEGRE L, Akotia MK, Wembulua BS, Pandi M, et al
    Circulating HBV RNA and conventional HBV markers in treatment-naive persons with HBV in Senegal.
    J Infect Dis. 2025 Apr 19:jiaf190. doi: 10.1093.
    >> Share

    March 2025
  40. PAUL RC, Gidding HF, Nazneen A, Banik KC, et al
    Population-based estimates of hepatitis E virus associated mortality in Bangladesh.
    J Infect Dis. 2025 Mar 13:jiaf134. doi: 10.1093.
    >> Share

  41. DOYLE TJ, Buck BH, Locksmith TJ, McGruder-Rawson BM, et al
    Genomic epidemiology of resurgent hepatitis A in Florida, 2018-2022.
    J Infect Dis. 2025 Mar 11:jiaf127. doi: 10.1093.
    >> Share

    February 2025
  42. GONZALEZ-SERNA A, Corma-Gomez A, Cano M, Ricardo RS, et al
    Influence of Cellular Aging on Liver Stiffness in HCV Patients Achieving Sustained Viral Response.
    J Infect Dis. 2025 Feb 19:jiaf087. doi: 10.1093.
    >> Share

  43. YANG XY, Li XD, Wu BY, Yang Q, et al
    A Model to Identify Grey-Zone Patients with Chronic Hepatitis B Requiring Antiviral Therapy: A Multicentre, Retrospective Study.
    J Infect Dis. 2025 Feb 17:jiaf070. doi: 10.1093.
    >> Share

    January 2025
  44. SUN Y, Chen Q, Liu Y, Jiao M, et al
    Decanoylcarnitine improves liver mitochondrial dysfunction in hepatitis B virus infection by enhancing fatty acid beta-oxidation.
    J Infect Dis. 2025 Jan 8:jiaf014. doi: 10.1093.
    >> Share

  45. SUSPENE R, Caval V, Khalfi P, Pitre E, et al
    Cobalt chloride-mimicked hepatocyte cell hypoxia induces TREX1 leading to Hepatitis B virus restriction.
    J Infect Dis. 2025 Jan 7:jiaf002. doi: 10.1093.
    >> Share

    December 2024
  46. ZHANG X, Nguyen VH, Kam LY, Barnett SD, et al
    Risk Stratification of Metabolic Risk Factors and Statin Use Associated With Liver and Nonliver Outcomes in Chronic Hepatitis B.
    J Infect Dis. 2024 Dec 12:jiae522. doi: 10.1093.
    >> Share

  47. WANG J, Genberg BL, Feder K, Kirk GD, et al
    Impact of pandemic-induced service disruptions and behavioral changes on HCV and HIV transmission amongst people who inject drugs: a modeling study.
    J Infect Dis. 2024 Dec 6:jiae599. doi: 10.1093.
    >> Share

  48. SACHITHANANDHAM J, Leep-Lazar J, Quinn J, Bowden K, et al
    Direct acting antivirals eradicate HCV from the liver quickly in people with HIV but do not fully reverse immune activation.
    J Infect Dis. 2024 Dec 4:jiae598. doi: 10.1093.
    >> Share

    October 2024
  49. TERRAULT NA, Sterling R, Lok AS, Ghany MG, et al
    HBV RNA as a Biomarker for Safe Antiviral Discontinuation: A Prospective Study of Nucleos(t)ide Analogue Withdrawal.
    J Infect Dis. 2024 Oct 30:jiae541. doi: 10.1093.
    >> Share

  50. TRUSCELLO E, Wang S, Young J, Sebastiani G, et al
    Changes in hepatic steatosis before and after direct acting antiviral treatment in people living with HIV and Hepatitis C coinfection.
    J Infect Dis. 2024 Oct 17:jiae487. doi: 10.1093.
    >> Share

  51. LU Y, Xin J, Liang X, Luo J, et al
    Plasma MERTK Is a Promising Biomarker for the Diagnosis and Prognosis of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure.
    J Infect Dis. 2024;230:957-969.
    >> Share

  52. YAO T, Li Y, Zhang Y, Sun Y, et al
    Immunogenicity, safety, and persistence induced by triple- and standard-strength four-dose hepatitis B vaccination regimens in hemodialysis patients: A multicenter, randomized, parallel-controlled trial in Six cities in Shanxi Province.
    J Infect Dis. 2024 Oct 8:jiae494. doi: 10.1093.
    >> Share

    July 2024
  53. HORN EK, Herrera-Restrepo O, Acosta AM, Simon A, et al
    The Burden of Hepatitis A Outbreaks in the United States: Health Outcomes, Economic Costs, and Management Strategies.
    J Infect Dis. 2024;230:e199-e218.
    >> Share

  54. NAKAYA Y, Onomura D, Hoshi Y, Yamagata T, et al
    Establishment of a hepatitis B virus reporter system harboring a HiBiT-tag in the PreS2 region.
    J Infect Dis. 2024 Jul 11:jiae353. doi: 10.1093.
    >> Share

  55. YAO Z, Gu Y, Lai X, Yang M, et al
    Trajectories of serum HBsAg during treatment and association with HBsAg loss in children with HBeAg-positive chronic hepatitis B: a latent class trajectory analysis.
    J Infect Dis. 2024 Jul 5:jiae349. doi: 10.1093.
    >> Share


  56. Correction to: Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose.
    J Infect Dis. 2024 Jul 3:jiae336. doi: 10.1093.
    >> Share

    June 2024
  57. BALAGOPAL A, Thio CL
    Hepatitis B surface antigen loss: what does integration have to do with a functional HBV cure?
    J Infect Dis. 2024 Jun 24:jiae327. doi: 10.1093.
    >> Share

  58. OSMANI Z, Beudeker BJB, Groothuismink ZMA, de Knegt RJ, et al
    B cell activation gene signature in blood and liver of HBeAg+ immune active chronic hepatitis B patients.
    J Infect Dis. 2024 Jun 7:jiae280. doi: 10.1093.
    >> Share

    May 2024
  59. GRUDDA T, Thomas DL, Kirk GD, Mehta SH, et al
    Hepatitis B virus DNA and RNA persist in liver after serologic recovery in persons with hepatitis C virus.
    J Infect Dis. 2024 May 23:jiae248. doi: 10.1093.
    >> Share

  60. MBISA JL, Lapp Z, Bibby DF, Phillips LT, et al
    Identification of two novel subtypes of hepatitis C virus genotype 8 and a potential new genotype successfully treated with direct acting antivirals.
    J Infect Dis. 2024 May 8:jiae253. doi: 10.1093.
    >> Share

    April 2024
  61. SELVAMANI SP, Khan A, Tay ESE, Garvey M, et al
    Hepatitis B virus and hepatitis C virus affect mitochondrial function through different metabolic pathways, explaining virus-specific clinical features of chronic hepatitis.
    J Infect Dis. 2024 Apr 24:jiae210. doi: 10.1093.
    >> Share

  62. BEGRE L, Boyd A, Plissonnier ML, Testoni B, et al
    Circulating HBV RNA and hepatitis B core-related antigen trajectories in persons with HIV/HBV coinfection and HBsAg loss on tenofovir therapy.
    J Infect Dis. 2024 Apr 16:jiae189. doi: 10.1093.
    >> Share

  63. SCHMIDT S, Mengistu M, Daffis S, Ahmadi-Erber S, et al
    Alternating Arenavirus Vector Immunization Generates Robust Polyfunctional Genotype Cross-Reactive Hepatitis B Virus-Specific CD8 T-Cell Responses and High Anti-Hepatitis B Surface Antigen Titers.
    J Infect Dis. 2024;229:1077-1087.
    >> Share

    March 2024
  64. WHITTAKER R, Midtbo JE, Klovstad H
    Monitoring progress towards the elimination of hepatitis C as a public health threat in Norway: a modelling study among people who inject drugs and immigrants.
    J Infect Dis. 2024 Mar 27:jiae147. doi: 10.1093.
    >> Share

  65. KAO CM, Rostad CA, Nolan LE, Peters E, et al
    A Phase 1, Double-blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin(R)) Vaccine in Healthy US Adults.
    J Infect Dis. 2024 Mar 27:jiae148. doi: 10.1093.
    >> Share

  66. KAMILI S, Wester C
    Advancing diagnosis of current HCV infection: A key to hepatitis C elimination in the United States.
    J Infect Dis. 2024 Mar 11:jiae127. doi: 10.1093.
    >> Share

  67. HESTERMAN MC, Fallon BS, Lynch KM, Weller ML, et al
    Growing Awareness: Limited Testing and Screening Bias for Hepatitis Delta Virus in Utah 2000-2021.
    J Infect Dis. 2024 Mar 8:jiae023. doi: 10.1093.
    >> Share

  68. ASLANIKASHVILI A, Rylander C, Manjavidze T, Gamkrelidze A, et al
    Relationship between hepatitis C infection and treatment status and COVID-19-related hospitalizations in Georgia.
    J Infect Dis. 2024 Mar 1:jiae103. doi: 10.1093.
    >> Share

    February 2024
  69. HORN EK, Herrera-Restrepo O, Acosta AM, Simon A, et al
    The Burden of Hepatitis A Outbreaks in the United States: Health Outcomes, Economic Costs, and Management Strategies.
    J Infect Dis. 2024 Feb 28:jiae087. doi: 10.1093.
    >> Share

  70. TU T, Ajoyan H, Nur Umami R, Veeraraghavan V, et al
    Inhibition of cellular factor TM6SF2 suppresses secretion pathways of Hepatitis B, Hepatitis C and Hepatitis D viruses.
    J Infect Dis. 2024 Feb 26:jiae098. doi: 10.1093.
    >> Share

  71. COLLAZOS J, Asensi V
    Non-invasive liver fibrosis markers in the evaluation of fibrosis regression after direct-acting antiviral (DAA) therapy.
    J Infect Dis. 2024 Feb 23:jiae095. doi: 10.1093.
    >> Share

  72. MUSONDA T, Wallace MS, Patel H, Martin OP, et al
    New window into hepatitis B in Africa: Liver sampling combined with single cell omics enables deep and longitudinal assessment of intrahepatic immunity in Zambia.
    J Infect Dis. 2024 Feb 9:jiae054. doi: 10.1093.
    >> Share

    January 2024
  73. RINGLANDER J, Stromberg LG, Stenback JB, Andersson ME, et al
    Enrichment reveals extensive integration of hepatitis B virus DNA in hepatitis delta-infected patients.
    J Infect Dis. 2024 Jan 25:jiae045. doi: 10.1093.
    >> Share

    October 2023
  74. IVANOVA REIPOLD E, Shilton S, Donolato M, Fernandez Suarez M, et al
    Molecular point of care testing for hepatitis C: available technologies, pipeline and promising future directions.
    J Infect Dis. 2023 Oct 28:jiad463. doi: 10.1093.
    >> Share

  75. FELD JJ
    What is needed to move toward single-step diagnosis of current HCV infection?
    J Infect Dis. 2023 Oct 13:jiad453. doi: 10.1093.
    >> Share

  76. FALADE-NWULIA O, Lesko CR, Fojo AT, Keruly JC, et al
    Hepatitis C treatment in people living with HIV: Potential to eliminate disease and disparity.
    J Infect Dis. 2023 Oct 5:jiad433. doi: 10.1093.
    >> Share

    September 2023
  77. FRICKER GP, Ghany MG, Mera J, Pinsky BA, et al
    Tools Needed to Support Same-day Diagnosis and Treatment of Current Hepatitis C Infection.
    J Infect Dis. 2023 Sep 22:jiad177. doi: 10.1093.
    >> Share

  78. CARTWRIGHT EJ, Patel PR
    Opportunities for enhanced prevention and control of hepatitis C through improved screening and testing efforts.
    J Infect Dis. 2023 Sep 22:jiad199. doi: 10.1093.
    >> Share

  79. JOHNSON LN, Gaynor AM, Wroblewski K, Buss SN, et al
    Maximizing Reflexive HCV RNA Testing of HCV Antibody-Reactive Samples Within United States Public Health Laboratories.
    J Infect Dis. 2023 Sep 22:jiad191. doi: 10.1093.
    >> Share

  80. TERRAULT N
    Down-Classification of Hepatitis C Virus Diagnostics: Implications for Screening and Diagnosis.
    J Infect Dis. 2023 Sep 22:jiad299. doi: 10.1093.
    >> Share

  81. PAGE K, Feinberg J
    What Hepatitis C (HCV) diagnostic tools are needed to advance diagnosis of current HCV infection in outreach settings and in a non-clinical setting?
    J Infect Dis. 2023 Sep 22:jiad269. doi: 10.1093.
    >> Share

  82. HANDANAGIC S, Shadaker S, Drobeniuc J, Tsereteli M, et al
    Lessons learned from global hepatitis C elimination programs.
    J Infect Dis. 2023 Sep 22:jiad198. doi: 10.1093.
    >> Share

  83. LOU S, Wang J, Chen J, Xie H, et al
    The Role of ALPK1 in Inhibiting Hepatitis B Virus Replication Facilitates the Identification of ALPK1 P660L Variant for Predicting Response to Pegylated Interferon alpha Therapy.
    J Infect Dis. 2023;228:694-703.
    >> Share

  84. CHIEN RN, Lu SN, Hui-Min Wu G, Yang WW, et al
    Policy and Strategy for Hepatitis C Virus Elimination at the National Level: Experience in Taiwan.
    J Infect Dis. 2023;228.
    >> Share

  85. KONDILI LA, Craxi L, Nava F, Babudieri S, et al
    From Prioritization to Universal Treatment: Successes and Challenges of Hepatitis C Virus Elimination in Italy.
    J Infect Dis. 2023;228.
    >> Share

  86. AARON A, Zhong H, Hiebert L, Zhuo Y, et al
    Hepatitis C Elimination in Moldova Is Feasible and Cost-Saving: A Modeling Study.
    J Infect Dis. 2023;228.
    >> Share

  87. QURESHI H, Mahmood H, Sabry A, Hermez J, et al
    Barriers and Strategies for Hepatitis B and C Elimination in Pakistan.
    J Infect Dis. 2023;228.
    >> Share

  88. WASITTHANKASEM R, Wanlapakorn N, Pimsing N, Posuwan N, et al
    Simplified Test-to-Treat Strategy for Hepatitis C in Thailand: The Phetchabun Model.
    J Infect Dis. 2023;228.
    >> Share

  89. NJUGUNA HN, Hiebert L, Harris A, Morgan RL, et al
    An Assessment of National Strategic Action Plans for Viral Hepatitis Elimination, 2016-2021.
    J Infect Dis. 2023;228.
    >> Share

  90. PRZYBYSZEWSKI EM, Chung RT
    Unmet Needs in the Post-Direct-Acting Antiviral Era: Hepatocarcinogenesis After Hepatitis C Virus Eradication.
    J Infect Dis. 2023;228.
    >> Share

  91. HUANG CF, Chen GJ, Hung CC, Yu ML, et al
    HCV Microelimination for High-risk Special Populations.
    J Infect Dis. 2023;228.
    >> Share

  92. ADDA D, James C, Peck R, Ali M, et al
    The Role of Nonprofit and Nongovernmental Organizations and People With Viral Hepatitis on the Path Toward Hepatitis C Virus Elimination.
    J Infect Dis. 2023;228.
    >> Share

  93. YU ML, Ward JW
    Sharing Lessons Learned to Build Effective Hepatitis Elimination Programs.
    J Infect Dis. 2023;228.
    >> Share

  94. UMUTESI J, Yu ML, Lesi O, Ward JW, et al
    Strategies for Removal of Barriers to Hepatitis C Elimination in Sub-Saharan Africa.
    J Infect Dis. 2023;228.
    >> Share

  95. SPAULDING AC, Kennedy SS, Osei J, Sidibeh E, et al
    Estimates of Hepatitis C Seroprevalence and Viremia in State Prison Populations in the United States.
    J Infect Dis. 2023;228.
    >> Share


  96. Correction to: Evidence of Residual Ongoing Viral Replication in Chronic Hepatitis B Patients Successfully Treated With Nucleos(t)ide Analogues.
    J Infect Dis. 2023 Sep 7:jiad376. doi: 10.1093.
    >> Share

    May 2023
  97. THIO CL, Taddese M, Saad Y, Zambo K, et al
    HBeAg-negative single hepatocyte analysis shows transcriptional silencing and slow decay of infected cells with treatment.
    J Infect Dis. 2023 May 2:jiad124. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016